Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailOsteonecrosis in inflammatory bowel diseases: a review of the literature
Hauzeur, Jean-Philippe ULg; Malaise, Michel ULg; Gangji, V.

in Acta Gastro-Enterologica Belgica (2009), 72(3), 327-334

INTRODUCTION: Osteonecrosis (ON) of the femoral head can lead to femoral head collapse, necessitating total hip replacement. Reports of patients suffering from both ON and Inflammatory Bowel Diseases (IBD ... [more ▼]

INTRODUCTION: Osteonecrosis (ON) of the femoral head can lead to femoral head collapse, necessitating total hip replacement. Reports of patients suffering from both ON and Inflammatory Bowel Diseases (IBD) have prompted us to evaluate the relationship between ON and IBD, especially Crohn's disease and ulcerative colitis. METHODS: A review of the data from three new cases, along with data from all the published cases of patients presenting ON and IBD found through a systematic search of the Pub Med database. RESULTS: We encountered some diagnostic problems: The ON diagnosis could not be confirmed in some patients who did not meet the ON diagnostic criteria. Reviewed data was too weak to assess the exact incidence of ON in IBD. Corticosteroid therapy, especially in high dose regimens, is likely the most important etiological factor. No evidence supporting other physiopathological hypothesis, such as total parenteral nutrition, osteoporosis, or coagulation disorders, was found. Finally, the multifocal form of ON appears particularly common in IBD, with some patients presenting multiple lesions of the hip, shoulder, knee and talus. CONCLUSIONS: ON in IBD, which is frequently multifocal, appears to be a complication of corticosteroid therapy, especially when high doses are used. We recommend regular ON checkups for corticosteroid-treated IBD patients. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli, Rene; Burlet, Nansa; Cahall, David et al

in BONE (2008), 42(5), 841-7

A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The ... [more ▼]

A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is unknown; this rare condition also may occur in patients not receiving bisphosphonates. Case reports have discussed ONJ development in patients with multiple myeloma or metastatic breast cancer receiving bisphosphonates as palliation for bone metastases. These patients are also receiving chemotherapeutic agents that might impair the immune system and affect angiogenesis. The incidence or prevalence of ONJ in patients taking bisphosphonates for osteoporosis seems to be very rare. No causative relationship has been unequivocally demonstrated between ONJ and bisphosphonate therapy. A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative. [less ▲]

Detailed reference viewed: 30 (2 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
NEUPREZ, Audrey ULg; Coste, S; Rompen, Eric ULg et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the ... [more ▼]

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk. [less ▲]

Detailed reference viewed: 46 (14 ULg)
See detailOsteoporose : van bestrijding tot behandeling
Reginster, Jean-Yves ULg; Franchimont, P

in Medical Trends (1988), 7

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporose bij de bejaarde
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sfeer (2000), 103

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose chez la personne âgée
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sphere (1999), 103

Detailed reference viewed: 13 (5 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose d'involution chez la femme
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(4), 335-40

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches ... [more ▼]

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches were developed for the prevention and treatment of osteoporosis. Besides regular physical exercise and calcium rich diet, calcium supplementation can be suggested to both genders, after seventy years as well as systematic vitamin D supplementation in order to cope with the frequent lack observed in our country. Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens. Due to its prohibitive cost, nasal calcitonin should be only considered for very specific cases. In osteoporosis confirmed by bone densitometry or by occurrence of fractures, bisphosphonate (alendronate) reduces subsequent fracture rate. Fluoride salts can, in some cases, improve spinal symptomatic osteoporosis. The use of etidronate, a molecule from the past, should be avoided as much as possible and, at any rate, strictly restricted to its legal indication including women with several vertebral crush fractures and severely decreased bone mineral density. [less ▲]

Detailed reference viewed: 46 (3 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose en questions : plus dure sera la chute
Reginster, Jean-Yves ULg

in Stethoscopie Magazine (1996), 63

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailL'osteoporose involutive de la femme: strategie therapeutique. Un point de vue actualise du Belgian Bone Club.
Kaufman, J M; Body, J J; Boonen, S et al

in Revue Médicale de Liège (2000), 55(5), 443-8

Osteoporosis is now considered as a major public health issue and a serious threat for the quality of life of elderly women. Several new compounds are currently marketed for the prevention and treatment ... [more ▼]

Osteoporosis is now considered as a major public health issue and a serious threat for the quality of life of elderly women. Several new compounds are currently marketed for the prevention and treatment of involutional osteoporosis in women. Therefore, it is important to offer to the practitioners pragmatic solutions to be used for the rational management of this disorder. This article is the result of a national consensus offering practical guidelines for the management of osteoporotic patients, based on the current published data. [less ▲]

Detailed reference viewed: 42 (1 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose passée sous microscope
Reginster, Jean-Yves ULg

in Actualité Médicale Belge (1986), 112

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailL'ostéoporose postménopausique : un combat pour l'avenir
Lecart, MP; Denis, D; DEROISY, Rita ULg et al

in Contraception, Fertilité, Sexualité (1988), 2

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailOstéoporose postménopausique: le point sur la thérapeutique
Reginster, Jean-Yves ULg

in Medisearch (1993), 73

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailL'ostéoporose
Reginster, Jean-Yves ULg; Franchimont, P

in Reumatismo (1988), 31

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailL'ostéoporose
Reginster, Jean-Yves ULg

in Medipractice Digest (1993)

Detailed reference viewed: 11 (2 ULg)
See detailL'ostéoporose: une maladie qui s'évite
Bruyère, Olivier ULg

Conference (2000, March 18)

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailOsteoporosis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Cianferotti, Luisella et al

Book published by Future Medicine Ltd (2013)

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : the interest of a prospective vision
Gillet, Pierre ULg; Reginster-Haneuse, G; Reginster, Jean-Yves ULg

in Osteoporosis International (1996), 6(S1), 119

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : The interest of a prospective vision
Gillet, Pierre ULg; Gosset, Christiane ULg; Reginster, Jean-Yves ULg

in Calcified Tissue International (1997), 61

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Breart, G.; Cooper, C.; Meyer, O. et al

in Osteoporosis International (2010), 21

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female ... [more ▼]

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients. INTRODUCTION: We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment. METHODS: A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N = 11,546), osteoporotic women treated with alendronate (N = 20,084), or strontium ranelate (N = 2,408), and a sample of non-osteoporotic women (N = 115,009). Cohorts were compared using a Cox proportional hazards regression model. RESULTS: There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient-years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09-1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient-years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60-2.01) for strontium ranelate and 0.92 (95% CI, 0.63-1.33) for alendronate. CONCLUSION: This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients. [less ▲]

Detailed reference viewed: 51 (2 ULg)